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COVID-19 from a Perspective of Neuromuscular Diseases: Meeting 
the Challenges
Dear editor,
The new severe acute respiratory syndrome 
coronavirus 2 epidemic is imposing immense strain on 
the health systems in several countries. The growth of 
the epidemic has led the WHO to declare the 2019-
nCoV disease as a global pandemic [1]. Coronavirus 
disease 2019 (COVID-19) pandemic has the potential 
to affect patients with neuromuscular diseases. The 
evaluation of the overall risk of COVID-19 in patients with 
neuromuscular diseases depends on several factors: 
The specificity of the neuromuscular disease, the general 
condition, the presence of other comorbidities, age, and 
the type of immunosuppressive treatment they receive. 
It is important to emphasize the fact that most patients 
with neuromuscular disease are not expected to suffer 
from severe complications due to coronavirus infection. 
Corona infections can affect certain myopathies. In a 
recent study published in China, related to COVID-19 
is shown that hospitalized patients experienced 
fatigue and myalgia (44–70%) and increased creatine 
kinase (33%) in the serum [2]. Apart from this, a third 
of hospitalized patients infected with the coronavirus 
had rhabdomyolysis [3]. All of this point to the fact 
that coronavirus infection may be responsible for viral 
myositis. In addition, is the finding that some of the critical 
cases have developed polyneuropathy or myopathy [4]. 
On the other hand, it is well known that infection is a 
trigger for exacerbation of certain neuromuscular 
diseases. There are no data that measured the risk of 
exacerbation as a result of coronaviruses infection for 
neuromuscular disorders. However, in one retrospective 
study, COVID-19 infection was a leading reason for the 
exacerbation of myasthenia gravis [5]. As a result of 
this, an increased incidence of exacerbations of certain 
neuromuscular diseases should be expected, as well 
as the appearance of new clinical presentations during 
this pandemic. It is important to note that there are still 
no neuromuscular disease-specific recommendations 
for patients who are infected with the coronavirus. 
Observation is recommended in patients at high and 
medium risk, especially in those patients where there is 
a possibility of a decrease in respiratory function. Last 
but not least, we would like to emphasize the need for 
reorganization of clinical care for these patients [6]. The 
goal is to reduce exposure of patients to areas where 
the coronavirus could be found. Moreover, non-urgent 
or outpatient care is remarkably reduced. In conclusion, 
we must learn to apply our clinical practices to reduce 
the complications that may occur in patients with 
neuromuscular disease due to COVID-19. The primary 
goal is to develop evidence-based medical practices to 
reduce morbidity and mortality. Collaboration among 
institutions worldwide will be able to give us the data 
needed for planning management for neuromuscular 
disorders with COVID-19 and maintain clinical research 
against strong challenges.
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